Published in Transplantation on February 01, 1976
Thoracic duct drainage before and after cadaveric kidney transplantation. Surg Gynecol Obstet (1979) 2.33
Thoracic duct fistula and renal transplantation. Ann Surg (1979) 1.60
Thoracic duct drainage in organ transplantation: will it permit better immunosuppression? Transplant Proc (1979) 1.21
Late follow-up after thoracic duct drainage in cadaveric renal transplantation. Surg Gynecol Obstet (1981) 1.01
Prolonged thoracic-duct drainage in rheumatoid arthritis and systemic lupus erythematosus. West J Med (1979) 0.93
The technique of prolonged thoracic duct drainage in transplantation. Surg Gynecol Obstet (1980) 0.93
Preliminary evidence of dual-marked lymphocytes in thoracic duct lymph fluid. Transplant Proc (1980) 0.79
The migrant cells in allotransplants of heart, kidney and skin. III. The source and evolution of migrant cells in association with allotransplant fibroplasia. Br J Exp Pathol (1977) 0.75
Impact of chylothorax on the early post operative outcome after pediatric cardiovascular surgery. J Saudi Heart Assoc (2014) 0.75
DR-bearing T lymphocytes in thoracic duct lymph. Clin Immunol Immunopathol (1981) 0.75
Effect of preoperative thoracic duct drainage on canine kidney transplantation. J Invest Surg (1997) 0.75
Chylothorax after pediatric cardiac surgery complicates short-term but not long-term outcomes-a propensity matched analysis. J Thorac Dis (2017) 0.75
High efficiency polyoma DNA transfection of chloroquine treated cells. Nucleic Acids Res (1983) 9.94
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol (2003) 4.62
Replication of polyoma DNA in isolated nuclei. I. Characterization of the system from mouse fibroblast 3T6 cells. J Mol Biol (1972) 4.47
RNA-linked short DNA fragments during polyoma replication. Proc Natl Acad Sci U S A (1973) 4.42
Differential effects of human granulocytes and lymphocytes on human fibroblasts in vitro. Clin Exp Immunol (1968) 3.38
Non-contiguous segments of the polyoma genome required in cis for DNA replication. J Mol Biol (1982) 3.03
Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med (2007) 3.02
Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci attaching to human pharyngeal epithelial cells. J Exp Med (1983) 2.80
Hydroxyurea-induced accumulation of short fragments during polyoma DNA replication. I. Characterization of fragments. J Virol (1973) 2.57
Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant (2010) 2.56
The PapG adhesin of uropathogenic Escherichia coli contains separate regions for receptor binding and for the incorporation into the pilus. Proc Natl Acad Sci U S A (1989) 2.36
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia (2007) 2.35
Construction and analysis of viable deletion mutants of polyoma virus. J Virol (1979) 2.30
Hydroxyurea-induced accumulation of short fragments during polyoma DNA replication. II. Behavior during incubation of isolated nuclei. J Virol (1973) 2.27
Replication of polyoma DNA in isolated nuclei. II. Evidence for semi-conservative replication. J Mol Biol (1972) 2.10
HLA-matching and pretransplant blood transfusions in cadaveric renal transplantation--a changing picture with cyclosporin. Lancet (1986) 2.08
Severe and common side-effects of amphotericin B lipid complex (Abelcet) Bone Marrow Transplant (1998) 2.05
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 1.98
Identification of binding sites on the regulatory A subunit of protein phosphatase 2A for the catalytic C subunit and for tumor antigens of simian virus 40 and polyomavirus. Mol Cell Biol (1992) 1.83
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant (2011) 1.82
Polyclonal antibody secretion in human lymphocytes induced by killed staphylococcal bacteria and by lipopolysaccharide. Scand J Immunol (1977) 1.82
Sealing of gaps in duplex DNA by T4 DNA ligase. Nucleic Acids Res (1982) 1.81
Structural basis of the interaction of the pyelonephritic E. coli adhesin to its human kidney receptor. Cell (2001) 1.79
Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood (1992) 1.77
Cytotoxicity of human lymphocytes: antagonism between inducing processes. Nature (1968) 1.76
The role of proximity in the use of hospital emergency departments. Sociol Health Illn (1980) 1.67
Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol (2004) 1.66
Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant (1990) 1.65
Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient? Scand J Urol Nephrol Suppl (1980) 1.63
Characterization of polyoma mutants with altered middle and large T-antigens. J Virol (1981) 1.58
Intraosseous compared to intravenous infusion of allogeneic bone marrow. Bone Marrow Transplant (1998) 1.58
No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant (2008) 1.56
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant (2004) 1.55
Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant (2003) 1.54
Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol (1995) 1.53
Non-specific induction of cytotoxicity in normal human lymphocytes in vitro: studies of mechanism and specificity of the reaction. Clin Exp Immunol (1969) 1.53
Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol (1987) 1.52
Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood (1998) 1.51
Lactose repressor-operator DNA interactions: kinetic analysis by a surface plasmon resonance biosensor. Anal Biochem (1993) 1.50
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother (1991) 1.50
Ethidium-bromide-inhibited restriction endonucleases cleave one strand of circular DNA. Gene (1982) 1.49
Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol (2007) 1.46
Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant (2004) 1.45
Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Haematol (1994) 1.41
T-antigen expression by polyoma mutants with modified RNA splicing. EMBO J (1983) 1.39
Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther (1980) 1.39
Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant (2003) 1.39
Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg (2004) 1.39
Transplantation of peripheral blood progenitor cells from unrelated donors. Transplantation (1998) 1.37
Reversible renal failure during treatment with captopril. Br Med J (1979) 1.35
Correction of hyperbilirubinemia in the glucuronyltransferase-deficient rat by intraportal hepatocyte transplantation. Transplant Proc (1977) 1.35
Effect of neuraminidase on the stimulatory capacity of cells in human mixed lymphocyte cultures. Clin Exp Immunol (1971) 1.32
Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother (1986) 1.31
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
Deletion mapping of a short polyoma virus middle T antigen segment important for transformation. J Virol (1983) 1.29
Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis (1986) 1.28
Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy (2009) 1.27
Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant (1998) 1.27
Synthesis of polyoma DNA by isolated nuclei. Biochem Biophys Res Commun (1971) 1.26
Deterioration in glucose metabolism in pancreatic transplant recipients given cyclosporin. Lancet (1983) 1.26
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis (1985) 1.25
Serine protein kinase activity associated with rotavirus phosphoprotein NSP5. J Virol (1997) 1.22
Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant (2008) 1.22
Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion (1997) 1.21
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol (2006) 1.21
Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood (1992) 1.19
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood (2000) 1.19
Glycopeptides bind MHC molecules and elicit specific T cell responses. J Immunol (1993) 1.18
Experience with human liver grafts obtained after donor cardiac standstill. Transplant Proc (1987) 1.18
The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant (2000) 1.17
Renal carcinoma (hypernephroma) occurring in 5 siblings. J Urol (1972) 1.16
Prevention of kidney graft diabetic nephropathy by pancreas transplantation in man. Diabetes (1985) 1.13
An analysis of factors predisposing to chronic graft-versus-host disease. Exp Hematol (1985) 1.13
Successful outcome of segmental human pancreatic transplantation with enteric exocrine diversion after modifications in technique. Lancet (1982) 1.12
Inheritance of strabismus and the gain of using heredity to determine populations at risk of developing strabismus. Acta Ophthalmol Scand (1999) 1.12
Ischemic heart disease--major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation (1995) 1.11
The cytotoxic activity of lymphocytes from human lymph in vitro. Clin Exp Immunol (1974) 1.11
Induction of antibody synthesis in human B lymphocytes by different polyclonal B cell activators: evaluation by direct and indirect PFC assays. Immunol Rev (1979) 1.10
No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood (2001) 1.10
G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant (2003) 1.09
Immunization with glycosylated Kb-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. Eur J Immunol (1996) 1.08
Glutathione transferase in the urine: a marker for post-transplant tubular lesions. Kidney Int (1988) 1.08
Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation (1984) 1.08
High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol (2000) 1.08
Frequency of emergency department attendances as a predictor of mortality: nine-year follow-up of a population-based cohort. J Public Health Med (1990) 1.08
Synthesis of spacer-arm, lipid, and ethyl glycosides of the trisaccharide portion [alpha-D-Gal-(1----4)-beta-D-Gal-(1----4)-beta-D-Glc] of the blood-group Pk antigen: preparation of neoglycoproteins. Carbohydr Res (1984) 1.08
Identical-twin bone marrow transplants for leukemia. Ann Intern Med (1994) 1.07
Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant (1998) 1.07
Induction and suppression of the cytotoxic activity of human lymphocytes in vitro by heterologous anti-lymphocyte serum. Clin Exp Immunol (1969) 1.06
Multiple free viral DNA copies in polyoma virus-transformed mouse cells surviving productive infection. J Virol (1977) 1.06